Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151

Benzinga Newsdesk www.benzinga.com Negative 67.0%

Neg 67% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.